COMPASS Psilocybin Depression Data Excite Despite Safety Issues
Executive Summary
The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.
You may also be interested in...
Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates
While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.
Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates
While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.
More De-Risking Required Before Pharma Dives Into Psychedelics
One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.